Dried Blood Spot (DBS) sampling is being adopted in drug development, paediatric healthcare, and, more recently, patient compliance. We describe our positive experience with the platform, as well as the many advantages – and ongoing concerns – of this simple, stable, and versatile technology.
Sangeeta Tanna, Graham Lawson |
Collecting drops of blood from the heels of newborn babies and depositing them on specially prepared Guthrie cards, where they dry, is an established form of sampling. Analysis of the DBS extract has been used for decades as a method to screen newborns for the occurrence of specified diseases (see “Dried Blood Spot 101”).
Early DBS screening tests only needed to demonstrate the presence or absence of certain traits and were consequently qualitative in nature. However, in the past few years, improvements in the sensitivity of analytical instruments, especially mass spectrometers, have resulted in the drive to exploit the potential to quantify components extracted from dried blood spots, which in turn has unearthed significant challenges (see “Confronting Concerns”).
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.